View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Feb. 21, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		61,663,044
Entity Public Float			$ 1,004,924,956

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 88,438	$ 71,029
Restricted cash		1,840
Short-term investments	68,134	83,028
Accounts receivable, net of allowance for doubtful accounts of $418 and $471	34,842	42,521
Inventories	22,888	19,343
Prepaid expenses	1,925	1,658
Other current assets	3,085	2,486
Total current assets	219,312	221,905
PROPERTY AND EQUIPMENT, net	24,299	21,372
INTANGIBLE ASSETS, net	5,137	8,223
GOODWILL	18,521	20,083
LONG TERM INVESTMENTS	44,752	20,690
OTHER ASSETS	3,550	3,928
TOTAL ASSETS	315,571	296,201
CURRENT LIABILITIES:
Accounts payable	10,598	10,228
Deferred revenue	3,521	1,314
Accrued expenses	13,861	20,695
Total current liabilities	27,980	32,237
OTHER LIABILITIES	3,312	3,932
DEFERRED INCOME TAXES	901	1,951
COMMITMENTS AND CONTINGENCIES (Note 12)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 61,276 and 60,662 shares issued and outstanding	0	0
Additional paid-in capital	401,273	387,931
Accumulated other comprehensive loss	(18,706)	(10,340)
Accumulated deficit	(99,189)	(119,510)
Total stockholders' equity	283,378	258,081
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 315,571	$ 296,201

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 418	$ 471
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	61,276,000	60,662,000
Common stock, shares outstanding	61,276,000	60,662,000

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
NET REVENUES:
Total revenue	$ 181,743	$ 167,064	$ 128,198
COST OF PRODUCTS SOLD	68,130	68,108	40,171
Gross profit	113,613	98,956	88,027
OPERATING EXPENSES:
Research and development	16,250	13,365	9,754
Sales and marketing	30,609	28,532	29,652
General and administrative	38,325	29,321	28,356
Gain on litigation settlement		(12,500)
Total operating expenses	85,184	58,718	67,762
Operating income	28,429	40,238	20,265
OTHER INCOME	3,287	794	58
Income before income taxes	31,716	41,032	20,323
INCOME TAX EXPENSE	11,320	10,084	603
NET INCOME	$ 20,396	$ 30,948	$ 19,720
EARNINGS PER SHARE:
BASIC	$ 0.33	$ 0.52	$ 0.35
DILUTED	$ 0.33	$ 0.51	$ 0.35
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC	61,112	59,050	55,615
DILUTED	62,532	61,024	56,513
Product [Member]
NET REVENUES:
Total revenue	$ 165,428	$ 161,988	$ 106,924
Royalty [Member]
NET REVENUES:
Total revenue	9,653
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 6,662	$ 5,076	$ 21,274

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME	$ 20,396	$ 30,948	$ 19,720
OTHER COMPEHENSIVE INCOME (LOSS)
Currency translation adjustments	(8,003)	4,433	1,419
Unrealized loss on marketable securities	(363)	(553)
COMPREHENSIVE INCOME	$ 12,030	$ 34,828	$ 21,139

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2015	$ 159,436		$ 345,253	$ (15,639)	$ (170,178)
Beginning Balance, Shares at Dec. 31, 2015		55,705
Common stock issued upon exercise of options	2,656		2,656
Common stock issued upon exercise of options, Shares		405
Vesting of restricted stock	0	$ 0	0	0	0
Vesting of restricted stock, Shares		446
Purchase and retirement of common shares	(3,444)		(3,444)
Purchase and retirement of common shares, Shares		(555)
Compensation cost for restricted stock	2,861		2,861
Compensation cost for stock option grants	2,691		2,691
Compensation cost for performance stock units	511		511
Net income	19,720				19,720
Currency translation adjustments	1,419			1,419
Ending Balance at Dec. 31, 2016	185,850		350,528	(14,220)	(150,458)
Ending Balance, Shares at Dec. 31, 2016		56,001
Common stock issued upon exercise of options	31,670		31,670
Common stock issued upon exercise of options, Shares		4,413
Vesting of restricted stock	0	$ 0	0	0	0
Vesting of restricted stock, Shares		378
Purchase and retirement of common shares	(1,240)		(1,240)
Purchase and retirement of common shares, Shares		(130)
Compensation cost for restricted stock	2,705		2,705
Compensation cost for stock option grants	2,045		2,045
Compensation cost for performance stock units	2,223		2,223
Net income	30,948				30,948
Currency translation adjustments	4,433			4,433
Unrealized loss on marketable securities	(553)			(553)
Ending Balance at Dec. 31, 2017	258,081		387,931	(10,340)	(119,510)
Ending Balance, Shares at Dec. 31, 2017		60,662
Adoption of ASU 2014-9	(75)				(75)
Common stock issued upon exercise of options	$ 1,697		1,697
Common stock issued upon exercise of options, Shares	227	227
Vesting of restricted stock and performance stock units	$ 0	$ 0	0	0	0
Vesting of restricted stock and performance stock units, Shares		578
Purchase and retirement of common shares	(3,592)		(3,592)
Purchase and retirement of common shares, Shares		(191)
Compensation cost for restricted stock	6,357		6,357
Compensation cost for stock option grants	2,163		2,163
Compensation cost for performance stock units	6,717		6,717
Net income	20,396				20,396
Currency translation adjustments	(8,003)			(8,003)
Unrealized loss on marketable securities	(363)			(363)
Ending Balance at Dec. 31, 2018	$ 283,378		$ 401,273	$ (18,706)	$ (99,189)
Ending Balance, Shares at Dec. 31, 2018		61,276

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
OPERATING ACTIVITIES:
Net income	$ 20,396	$ 30,948	$ 19,720
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	15,237	6,973	6,063
Depreciation and amortization	6,451	6,075	5,687
Other non-cash amortization	771	327	(47)
Unrealized foreign currency (gain) loss	(400)	156	122
Loss (gain) on sale of fixed assets		(25)	(28)
Deferred income taxes	(919)	(649)	(529)
Changes in assets and liabilities
Accounts receivable	6,635	(22,116)	(576)
Inventories	(3,857)	(7,391)	1,476
Prepaid expenses and other assets	(366)	(384)	(652)
Accounts payable	208	5,157	46
Deferred revenue	2,240	(93)	(8,350)
Accrued expenses and other liabilities	(7,306)	9,178	1,666
Net cash provided by operating activities	39,090	28,156	24,598
INVESTING ACTIVITIES:
Purchases of investments	(163,763)	(161,269)	(34,133)
Proceeds from maturities and redemptions of investments	152,680	69,253	30,421
Purchases of property and equipment	(6,344)	(4,337)	(4,353)
Net cash used in investing activities	(17,427)	(96,353)	(8,065)
FINANCING ACTIVITIES:
Payments for debt issue costs			(367)
Proceeds from exercise of stock options	1,701	31,675	2,656
Repurchase of common stock	(3,592)	(1,240)	(3,444)
Net cash provided by (used in) financing activities	(1,891)	30,435	(1,155)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(4,203)	841	318
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	15,569	(36,921)	15,696
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD	72,869	109,790	94,094
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD	$ 88,438	$ 72,869	$ 109,790

The Company

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	THE COMPANY:

Our business is comprised of two segments. Our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular collections systems or “DNAG” business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.

Our OSUR diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. We also manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery or freezing. These cryosurgical products are sold in both professional and over-the-counter (“OTC”) markets in North America, Europe, Central and South America, and Australia.

Our DNAG, or molecular collection systems business, is operated by our subsidiary, DNA Genotek Inc., a company based in Ottawa, Canada. DNAG’s Oragene^® DNA sample collection kit provides an all-in-one system for the collection, stabilization, transportation and storage of DNA from human saliva. We also sell research use only sample collection products into the microbiome and tuberculosis markets and we offer our customers a suite of genomics and microbiome services, which range from package customization and study design optimization to extraction, analysis and reporting services. We serve customers worldwide, including many leading research universities and hospitals.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiary, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Supplemental Cash Flow Information

In 2018, 2017 and 2016, we paid income taxes of $17,126, $4,309 and $1,123, respectively.

In 2018, 2017 and 2016, we recorded through the consolidated statements of income an increase (decrease) in our allowance for doubtful accounts of $(27), $172 and $40, respectively. We had $11, $200 and $369 in write-offs against the allowance for doubtful accounts in 2018, 2017, and 2016, respectively.

As of December 31, 2018, 2017 and 2016, we had accruals for purchases of property and equipment of $964, $449 and $302, respectively.

Investments

We consider all investments in debt securities to be available-for-sale securities. These securities are comprised of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The following is a summary of our available-for-sale securities as of December 31, 2018 and 2017:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
December 31, 2017
Guaranteed investment certificates	$	22,261	$	—	$	—		$	22,261
Corporate bonds		82,010		—		(553	)		81,457
Total available-for-sale securities	$	104,271	$	—	$	(553	)	$	103,718
At December 31, 2018, maturities of our available- for-sale securities were as follows:
Less than one year	$	68,702	$	—	$	(568	)	$	68,134
Greater than one year	$	45,101	$	—	$	(349	)	$	44,752

Accounts Receivable

Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage under a fixed-formula methodology.

Property and Equipment

Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of income.

Intangible Assets

Intangible assets consist of a customer list, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of seven to fifteen years.

Impairment of Long-Lived Assets

We assess the recoverability of our long-lived assets, which include property and equipment and intangible assets, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets.

Goodwill

Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

We performed our annual impairment assessment as of July 31, 2018 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying value. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of December 31, 2018, we believe no indicators of impairment exist.

Revenue

In January 2018, we adopted ASU 2014-09, Revenue from Contracts with Customers, using the modified retrospective method applied to contracts existing as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance.

Upon adoption, we recorded a reduction of $75 to the opening balance of accumulated deficit as of January 1, 2018. This adjustment is related to the change in revenue recognition associated with our drug testing kit sales. Sales of our drug testing kits include two performance obligations: sales of the device and laboratory services. Under this new accounting standard, we adjusted the allocation of the transaction price to the performance obligations and the estimate of unexercised rights (“breakage”) associated with the contracts. Prior to the adoption of the new guidance, we used the residual value method to allocate the transaction prices. With the adoption of ASU 2014-09, we allocated transition prices based upon the stand-alone selling price, or fair value method. This change in methodology also impacted our estimated breakage amount.

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

The adoption of this new standard had an immaterial impact on our 2018 reported total revenues and operating income, as compared to what would have been reported under the prior standard. We expect the impact of adoption in future periods to continue to be immaterial. Our accounting policies under the new standard were applied prospectively and are noted below.

Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that reflects the consideration we are entitled to, net of allowances for any discounts or rebates.

Our net revenues recorded for sales of the OraQuick^® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising, discounts, rebates, and chargebacks. The allowance for expected returns is an estimate established by management, based upon currently available information, and is adjusted to reflect known changes in the factors that impact this estimate. Other customer allowances are at contractual rates and are recorded as a reduction of gross revenue when recognized in our consolidated statements of operations.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Arrangements with multiple-performance obligations. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or services is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on their respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred for the related goods or services.

Other revenues. Other revenues consist primarily of exclusivity revenues, royalty income, funding of research and development efforts and cost reimbursements under a charitable support agreement. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Funding and charitable support reimbursements are recorded as the activities are being performed in accordance with the respective agreements.

On June 10, 2014, we entered into a Master Program Services and Co-Promotion Agreement with AbbVie to co-promote our OraQuick^® HCV test in the United States. On June 30, 2016, we mutually agreed to terminate our agreement effective December 31, 2016. Accordingly, we did not record any revenue from this co-promotion agreement during 2018 and 2017. During 2016, $18,951 in exclusivity revenues were recognized and recorded as other revenue in our consolidated statements of income.

As part of our litigation settlement agreement with Ancestry.com DNA LLC (“Ancestry”) and its contract manufacturer, we granted Ancestry a royalty-bearing, non-exclusive, worldwide license to certain patents and patent applications related to the collection of DNA in human saliva. The license granted to Ancestry is limited to saliva DNA collection kits sold or used as part of Ancestry’s genetic testing service offerings and does not cover the sale or use of collection kits outside of Ancestry’s business. During the year ended December 31, 2018, we recorded $9,653, in royalty income under this agreement.

On June 12, 2015, we were awarded a grant for up to $10,400 in total funding from the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (“BARDA”) related to our OraQuick^® Ebola rapid antigen test. The three-year, multi-phased grant, with an original expiration date of October 2018, was recently amended and extended through December 31, 2019, included an initial commitment of $1,800 and options for up to an additional $8,600 to fund certain clinical and regulatory activities. In September 2015 and July 2017, BARDA exercised options to provide $7,200 and $1,330, respectively, in additional funding for our OraQuick^® Ebola test. Amounts related to this grant are recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During 2018, 2017 and 2016, $2,988, $1,999 and $1,707, respectively, were recognized in connection with this grant.

In August 2016, we were awarded a contract for up to $16,600 in total funding from BARDA related to our rapid Zika test. The initial six-year, multi-phased contract includes an initial commitment of $7,000 and options for up to an additional $9,600 to fund the evaluation of additional product enhancements, and clinical and regulatory activities. In May 2017, BARDA exercised an option to provide $2,600 in additional funding for our rapid Zika test. Funding received under this contract is recorded as other revenue in our consolidated statements of income as the activities are being performed and the related costs are incurred. During 2018, because of difficulties in completing development and optimizing our Zika test and because of significant uncertainty regarding the future commercial demand for this product, the scope of work covered by this contract was reduced. As a result, our contract with BARDA will be essentially completed in the first quarter of 2019. During 2018, 2017, and 2016, $1,963, $2,388 and $616 respectively, were recognized in connection with this grant.

In June 2017, we entered into a four-year Charitable Support Agreement with the Bill & Melinda Gates Foundation (“Gates Foundation”) that will enable us to offer our OraQuick^® HIV Self-Test at an affordable price in 50 developing countries with funding from the Gates Foundation. The funding will consist of support payments tied to volume of product sold by us and reimbursement of certain related costs. The funding from the Gates Foundation will be in an aggregate amount not to exceed $20,000 over the four-year term or $6,000 each year of the agreement. Funding received under this agreement in the form of support payments for product purchases is recorded as a component of product revenue. During 2018 and 2017, $4,429 and $1,047, respectively, of support payments were recognized in product revenue in connection with this agreement. Funding received in the form of reimbursement of certain related costs is recorded as other revenue in our consolidated statements of income. During 2018 and 2017, $1,711 and $689, respectively, was recognized in other revenue in connection with this agreement.

Deferred Revenue

We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of December 31, 2018 and 2017 includes customer prepayments of $2,057 and $1,045, respectively. Deferred revenue as of December 31, 2018 and 2017 also included $1,464 and $269, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of contract was determined and revenue is recognized at that rate when the product is delivered to the customer.

Financing and Payment. Our payment terms vary by the type and location of our customer and products or services offered. Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Other than for sales of our OraQuick® In-Home HIV test to the retail trade, we generally do not grant product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

As a result of the return rights granted to our customers for our OraQuick® In-Home HIV test, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of December 31, 2018 and December 31, 2017, the reserve for sales returns and allowances was $191 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Sales commissions are expensed when incurred if the amortization period is one year or less. These costs are recorded in sales and marketing expense in the consolidated statements of operations. If the amortization period exceeds one year, we defer the cost of the commission and expense it over the life of the related sales contract.

Revenues by product. The following table represents total net revenues by product line:

	Twelve Months Ended December 31,
	2018		2017		2016
OraQuick®	$	53,851	$	60,558	$	47,134
Oragene®		75,850		69,184		29,454
Intercept®		7,709		8,125		8,351
Histofreezer®		8,983		10,312		11,628
Other products		19,035		13,809		10,357
Net product revenues		165,428		161,988		106,924

Royalty income		9,653		-		-
AbbVie exclusivity		-		-		18,951
BARDA funding		4,951		4,387		2,323
Charitable support reimbursement		1,711		689		-
Other revenues		16,315		5,076		21,274

Net revenues	$	181,743	$	167,064	$	128,198

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	December 31,
	2018		2017		2016
United States	$	136,847	$	121,458	$	99,758
Europe		11,062		11,827		11,646
Other regions		33,834		33,779		16,794
	$	181,743	$	167,064	$	128,198

Customer and Vendor Concentrations

One of our customers accounted for 7% and 37% of our accounts receivable as of December 31, 2018 and 2017, respectively. The same customer accounted for approximately 24% and 25% of our net consolidated revenues for the year ended December 31, 2018 and 2017, respectively. Another customer accounted for approximately 15% of our net consolidated revenues for the year ended December 31, 2016.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Research and Development

Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2018, 2017, and 2016, we incurred $763, $717, and $626, respectively, in advertising expenses.

Stock-Based Compensation

We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than purchase shares in the open market.

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, as well as operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates for the respective taxing jurisdiction that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We assess the realizability of our net deferred tax assets on a quarterly basis. If, after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized, we reduce our net deferred tax assets by a valuation allowance. The realization of the net deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of our net operating loss carryforwards.

Foreign Currency Translation

The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income (expense) in our consolidated statements of income were $831, $(1,442), and $(607) for the years ended December 31, 2018, 2017, and 2016, respectively.

Earnings Per Share

Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period.

The computations of basic and diluted earnings per share are as follows:

	Year ended December 31,
	2018		2017			2016
Net income	$	20,396		$	30,948	$	19,720
Weighted average shares of common stock outstanding:
Basic		61,112			59,050		55,615
Dilutive effect of stock options, restricted stock, and performance stock units		1,420			1,974		898
Diluted		62,532			61,024		56,513
Earnings per share:
Basic	$	0.33		$	0.52	$	0.35
Diluted	$	0.33		$	0.51	$	0.35

For the years ended December 31, 2018, 2017, and 2016, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 291, 180, and 2,546 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at December 31, 2018 consists of $17,789 of currency translation adjustments and $917 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio. Accumulated other comprehensive loss at December 31, 2017 consists of $9,787 of currency translation adjustments and $553 of net unrealized losses on marketable securities.

Fair Value of Financial Instruments

As of December 31, 2018 and 2017, the carrying values of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 1 instruments as of December 31, 2018 and 2017.

Included in cash and cash equivalents at December 31, 2018 and 2017, was $21,631 and $40,760 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of December 31, 2018 and 2017 was $3,884 and $3,514, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and other assets with the same amounts included in accrued expenses and other liabilities in the accompanying consolidated balance sheets.

In 2017, we purchased certificates of deposit (“CDs”) from a commercial bank. The CDs bear interest at rates ranging from 0.89% to 1.03% and matured periodically through January 22, 2018. The carrying values of the CDs approximate their fair value. These CDs served as collateral for certain standby letters of credit and are reported as restricted cash on the accompanying consolidated balance sheets as of December 31, 2017. We have no restricted cash as of December 31, 2018.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases, which requires entities to begin recording assets and liabilities from leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018, using a modified retrospective approach by recognizing a cumulative effect adjustment to the opening balance of retained earnings. Early adoption is permitted. In July 2018, companies were provided with an option to apply the modified retrospective approach as of either the date of adoption or as of the earliest date presented. We adopted this guidance effective January 1, 2019 by applying the modified retrospective approach as of the date of adoption with the available practical expedients.

We continue to utilize a comprehensive approach to assess the impact of this guidance on our financial statements and related disclosures, including the increase in the assets and liabilities on our balance sheet. We are substantially complete with our comprehensive review of our lease portfolio including significant leases by geography and by asset type that will be impacted by the new guidance, and enhancing our controls. In addition, we are progressing on the implementation of a new application for administering our leases and facilitating compliance with the new guidance. The new guidance will require us to record all leases, including operating leases, on the consolidated balance sheet as a right-of-use asset and corresponding liability for future payment obligations. Adoption of the standard will result in the estimated recognition of right-of-use assets of less than 2% of total assets and lease liabilities of less than 16% of total liabilities, and will not have a material impact to the consolidated income statement.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance related to cash flows presentation and is effective for annual reporting periods beginning after December 15, 2017. We adopted ASU 2016-15 on January 1, 2018 and this standard did not have a material impact on our consolidated financial statements.

In March 2017, the FASB issued ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities, which shortens the premium amortization period for purchased non-contingently callable debt securities. Shortening the amortization period is generally expected to more closely align the interest income recognition with the expectations incorporated in the market pricing of the underlying securities. This ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted. We adopted ASU 2017-08 on January 1, 2018 and this standard did not have a material impact on our consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, to provide clarity to which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting as described in Topic 718. This update is effective for annual periods and interim periods in fiscal years beginning after December 15, 2017 with early adoption permitted. We adopted ASU 2017-09 on January 1, 2018 and this standard did not have a material impact on our consolidated financial statements.

Inventories

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories

3.	INVENTORIES:

	December 31,
	2018		2017
Raw materials	$	14,092	$	10,299
Work in process		544		199
Finished goods		8,252		8,845
	$	22,888	$	19,343

Property and Equipment

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Property and Equipment

4.	PROPERTY AND EQUIPMENT:

	December 31,
	2018			2017
Land	$	1,118		$	1,118
Buildings and improvements		22,480			20,726
Machinery and equipment		29,017			26,685
Computer equipment and software		9,632			9,131
Furniture and fixtures		2,681			2,194
Construction in progress		2,168			897
		67,096			60,751
Less accumulated depreciation		(42,797	)		(39,379	)
	$	24,299		$	21,372

Depreciation expense was $3,828, $3,434, and $3,149 for 2018, 2017, and 2016, respectively.

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

5.	GOODWILL AND OTHER INTANGIBLE ASSETS:

The changes in goodwill are as follows:

	December 31,
	2018			2017
Balance as of January 1	$	20,083		$	18,793
Change related to foreign currency translation		(1,562	)		1,290
Balance as of December 31	$	18,521		$	20,083

Intangible assets consist of the following:

			December 31, 2018
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,186	$	(6,532	)	$	2,654
Patents and product rights		10		5,400		(4,708	)		692
Acquired technology		7		7,135		(7,135	)		-
Tradename		15		3,521		(1,730	)		1,791
			$	25,242	$	(20,105	)	$	5,137

			December 31, 2017
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,960	$	(6,112	)	$	3,838
Patents and product rights		10		5,400		(4,258	)		1,142
Acquired technology		7		7,737		(6,690	)		1,047
Tradename		15		3,818		(1,622	)		2,196
			$	26,915	$	(18,692	)	$	8,223

Patents and products rights are made up of the following:

	December 31,
	2018			2017
HIV-related	$	900		$	900
HCV-related		4,500			4,500
		5,400			5,400
Less accumulated amortization		(4,708	)		(4,258	)
	$	692		$	1,142

Amortization expense for 2018, 2017, and 2016 was $2,623, $2,641, and $2,538, respectively.

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:

2019		1,617
2020		1,409
2021		1,165
2022		245
2023		245
Beyond		456
	$	5,137

Accrued Expenses

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Accrued Expenses

6.	ACCRUED EXPENSES:

	December 31,
	2018		2017
Payroll and related benefits	$	8,926	$	9,265
Professional fees		1,541		1,064
Income taxes payable		1,447		6,469
Royalties		—		845
Other		1,947		3,052
	$	13,861	$	20,695

Credit Facility

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Credit Facility

7.	CREDIT FACILITY:

On September 30, 2016, we entered into a credit agreement (the “Credit Agreement”) with a commercial bank. The Credit Agreement, as amended on December 20, 2017, provides for revolving extensions of credit in an initial aggregate amount of up to $10,000 (inclusive of a letter of credit sub-facility of $2,500). Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets. There were no borrowings under the facility during 2018 and 2017.

Borrowings under the Credit Agreement are subject to compliance with borrowing base limitations tied to eligibility of accounts receivable. Interest under the Credit Agreement is payable at the London Interbank Offered Rate for one, two, three or six-month loans, as selected by the Company, plus 2.50% per year. The Credit Agreement is subject to an unused line fee of 0.375% per year on the unused portion of the commitment under the Credit Agreement during the revolving period. The maturity date of the Credit Agreement is September 30, 2019.

In connection with the Credit Agreement, under certain circumstances, we must comply with a minimum fixed charge coverage ratio of 1.10 to 1.00, measured as of the last day of each fiscal month and for the twelve-fiscal month period ending on such date. As of December 31, 2018 and 2017, we were in compliance with all applicable covenants in the Credit Agreement.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

8.	INCOME TAXES:

Income before income tax expense consists of the following:

	Years Ended December 31,
	2018			2017		2016
United States	$	(11,728	)	$	2,270	$	18,492
Canada		43,444			38,762		1,831
	$	31,716		$	41,032	$	20,323

The components of income tax expense are as follows:

	Years Ended December 31,
	2018			2017			2016
Current
Federal	$	—		$	—		$	—
State		155			—			250
Canada		12,084			10,733			882
		12,239			10,733			1,132
Deferred
Federal		9,200			10,297			6,508
State		1,011			(827	)		569
Canada		(919	)		(649	)		(529	)
		9,292			8,821			6,548
Decrease in valuation allowance		(10,211	)		(9,470	)		(7,077	)
		(919	)		(649	)		(529	)
Total income tax expense	$	11,320		$	10,084		$	603

For the years ended December 31, 2018, 2017, and 2016 we recorded foreign income tax expense of $11,165, $10,084, and $353, respectively.

The Tax Cuts and Jobs Act

On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Tax Act”) that instituted fundamental changes to the taxation on multinational corporations. Although the Tax Act is generally effective January 1, 2018, U.S. generally accepted accounting principles requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017. Among the numerous provisions, the Tax Act includes three provisions in particular which require consideration for financial reporting: a permanent reduction in the corporate tax rate to 21%, a one-time tax on undistributed foreign earnings, and a new U.S. tax on global intangible low taxed income (“GILTI”) which is a tax on certain earnings of foreign affiliates.

The reduction in the U.S. corporate tax rate to 21% became effective in 2018. This change resulted in a re-measurement of our net deferred tax balance at the end of 2017 with no net financial statement impact due to a comparable decrease in our deferred tax valuation allowance.

The one-time tax on undistributed and previously untaxed post-1986 foreign earnings and profits (E&P) of foreign affiliates owned by U.S. shareholders as of December 31, 2017 was analyzed for our Canadian subsidiary. For the 2017 federal tax return filed during 2018 our U.S. federal taxable loss exceeded and offset the provisional mandatory repatriation net inclusion and as such, no additional taxes were due as a result of the deemed repatriation of these foreign earnings.

In addition, the Tax Act also included changes to the taxation of foreign earnings by implementing a dividend exemption system, expansion of the current anti-deferral rules, a minimum tax on low-taxed foreign earnings and new measures to deter base erosion and promote U.S. production. The Tax Act also included repeal of the corporate alternative minimum tax, expensing of capital investment, changes to the Federal net operating loss (“NOL”) utilization and carryforward rules, and limitations of the deduction for interest expense and certain employee compensation.

As a result of the complex impact of the Tax Act, the SEC provided guidance under Staff Accounting Bulletin No. 118 (“SAB 118”) that allowed the Company to record provisional amounts as of December 31, 2017 for the impact of the Tax Act, provided that the provisional amounts could be reasonably determined and with the requirement that the final accounting be completed in a period not to exceed one year from the date of enactment. As of December 31, 2018, the Company has completed the accounting for the tax effects of the Tax Act, and therefore, has recorded final amounts which include:

(a)

The impact of the one-time transition tax on existing net operating loss and foreign tax credit carryforwards generated, as well as the related offsetting valuation allowances. The final one-time transitioned income reported on the 2017 federal tax return filed in 2018 was $17,724. This amount decreased both the net operating loss carryforward as well as the corresponding valuation allowance. Based on updated guidance, in 2018 the Company elected to deduct foreign taxes and therefore did not generate foreign tax credits. As such the deferred tax asset recorded as of December 31, 2017 associated with foreign tax credits was reversed in 2018.

(b)

The valuation allowance for the Company’s deferred tax assets as of December 31, 2017, was primarily dependent on forecasted future taxable income in the U.S. and Canada and was impacted by the provisions of the Tax Act. The primary impact of the Tax Act was the lowering of the statutory rate to 21%. This lowered the deferred tax assets and corresponding valuation allowance by $11,273.

The Tax Act imposed a U.S. tax on GILTI that is earned by certain foreign affiliates owned by a U.S. shareholder effective in 2018. GILTI is generally intended to impose tax on the earnings of a foreign corporation that are deemed to exceed a certain threshold return relative to the underlying tangible property. The GILTI computation for 2018 was completed and is reflected in this year’s income tax provision. The Company has made a policy election related to its treatment of GILTI and will treat it as a current period expense in the reporting period in which the tax is incurred.

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2018, 2017, and 2016 is as follows:

	2018				2017				2016
Statutory U.S. federal income tax rate		21.0		%		34.0		%		34.0		%
Deemed repatriation tax		10.9				7.8				—
GILTI tax		22.2				—				—
Statutory rate change, deferred tax impact		—				29.4				—
Nondeductible executive compensation		4.8				—				—
Impact of share-based payment awards		0.6				(16.0	)			—
Tax effect of Canadian items		6.8				(8.3	)			(1.9	)
State income taxes, net of federal benefit		2.8				(1.1	)			2.0
Nondeductible expenses and other		(1.2	)			1.9				3.7
Change in valuation allowance, federal and state		(32.2	)			(23.1	)			(34.8	)
Effective tax rate		35.7		%		24.6		%		3.0		%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our deferred tax assets (liabilities) as of December 31, 2018 and 2017 are as follows:

	2018			2017
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	10,812		$	15,338
Inventories		1,005			1,179
Capitalized research and development costs		1,697			2,402
Accruals and reserves currently not deductible		3,767			3,103
Acquired intangible assets		(1,153	)		(1,825	)
Depreciation and amortization		(1,082	)		(621	)
Stock-based compensation		1,248			976
Tax credit carryforwards		1,819			6,722
Net deferred tax asset		18,113			27,274
Valuation allowance		(19,014	)		(29,225	)
Net deferred tax liability	$	(901	)	$	(1,951	)

In assessing the realizability of our deferred tax asset, we consider all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent upon several factors, including the generation of sufficient taxable income prior to the expiration of the NOL carryforwards. In 2008, we established a full valuation allowance against our U.S. deferred tax asset, and management believes the full valuation allowance is still appropriate as of December 31, 2018 and 2017 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal income tax benefit was recorded for the years ended December 31, 2018, 2017, or 2016. The valuation allowance primarily decreased by $10,211 in 2018 due to utilization of federal and state net operating losses due to the GILTI inclusion in taxable income.

Our Federal NOL carryforwards expire as follows:

Year of Expiration	NOLs
2030 - 2034	$	36,100
2035 - 2037		11,260
	$	47,360

The new accounting guidance under ASU 2016-09 allows for the recognition of excess tax benefits associated with stock-based compensation awards regardless of whether the deduction reduces taxes payable. On January 1, 2017, we recorded a cumulative adjustment to retained earnings of $3,391 to recognize the increase in our net operating loss carryforwards from the cumulative excess tax benefits not recognized in periods prior to January 1, 2017. A corresponding $3,391 increase to our valuation allowance associated with this tax benefit was also recorded to retained earnings thereby resulting in no impact to retained earnings.

The Tax Reform Act of 1986 contains provisions under Internal Revenue Code (“IRC”) Section 382 that limit the annual amount of federal and state NOL carryforwards that can be used in any given year in the event a significant change in ownership. We do not believe that there is a Section 382 limitation that will impair our future ability to utilize NOLs to offset our future taxable income. We continue to review ownership changes on an annual basis and we do not believe we have had a subsequent ownership change that would impact the NOLs.

Effective January 1, 2018, there is a transition to a participation exemption system whereby distributions from foreign subsidiaries to U.S. shareholders are generally exempt from taxation. Our intention is to continue to permanently reinvest the historical undistributed earnings of our Canadian subsidiary to the extent that we will not incur any additional tax expense associated with foreign withholding or other local tax expense on the future cash transfers. As such, deferred taxes have not been recorded on the unremitted earnings of the Canadian subsidiary.

As of December 31, 2018, our gross unrecognized tax benefits totaled $1,676, and based upon the valuation allowance for our U.S. operations, the recognition of any tax benefit would not impact our effective tax rate. We record interest and penalties related to unrecognized tax benefits as a component of income tax expense. Interest and penalties were immaterial in 2018, 2017 and 2016. As a result of our net operating loss carryforward position, we are subject to audit by the Internal Revenue Service since our inception, as well as by several state jurisdictions for the years ended September 30, 1998 through December 31, 2018.

A reconciliation of our unrecognized tax benefits is as follows:

	2018			2017			2016
Balance as of January 1	$	1,663		$	2,084		$	2,088
Additions for tax positions of prior periods		44			—			-
Reductions for tax positions of prior periods		(31	)		(421	)		(4	)
Balance as of December 31	$	1,676		$	1,663		$	2,084

Stockholders' Equity

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Stockholders' Equity

9.	STOCKHOLDERS’ EQUITY:

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

As of December 31, 2018, 3,704 shares were available for future grants under the Stock Plan.

Under the terms of the Stock Plan, nonqualified stock options may be granted to eligible employees, including our officers at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may be either unlimited or have a specified period in which to vest and be exercised. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2018			2017			2016
Risk-free interest rate⁽¹⁾		2.60	%		2.22	%		1.76	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		43	%		43	%		46	%
Expected life of stock options (in years)⁽²⁾		6			7			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2018, 2017 and 2016 was $9.15, $4.71 and $2.91, respectively.

Compensation expense recognized in the financial statements related to stock options was as follows:

	Years Ended December 31,
	2018			2017			2016
Total compensation cost during the year	$	2,163		$	2,045		$	2,691
Amounts capitalized into inventory during the year		(420	)		(371	)		(270	)
Amounts recognized in cost of products sold for amounts previously capitalized		396			276			212
Amounts charged against income	$	2,139		$	1,950		$	2,633

The aggregate intrinsic value of options exercised during the years ended December 31, 2018, 2017, and 2016 (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) was $2,314, $35,631, and $763, respectively.

The following table summarizes the stock option activity under the Stock Plan:

	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2018		1,201			8.04
Granted		171			20.35
Exercised		(227	)		7.47
Expired		(38	)		6.05
Forfeited		(24	)		7.53
Outstanding on December 31, 2018		1,083		$	10.19		6.2	$	3,047
Vested or expected to vest as of December 31, 2018		1,083		$	10.19		6.2	$	3,047
Exercisable on December 31, 2018		776		$	8.81		5.3	$	2,434

As of December 31, 2018, there was $1,677 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 1.9 years.

Net cash proceeds from the exercise of stock options were $1,701, $31,675 and $2,656 for the years ended December 31, 2018, 2017, and 2016, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding as of December 31, 2018:

Options outstanding								Options exercisable
Range of exercise prices		Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$	5.37		121		6.9	$	5.37		64	$	5.37
$	5.47		3		6.7		5.47		2		5.47
$	5.71		120		4.4		5.71		120		5.71
$5.79 - $7.28			114		5.4		7.06		112		7.06
$7.33 - $8.63			74		3.2		8.30		73		8.32
$	8.87		137		8.0		8.87		53		8.87
$	8.93		6		8.0		8.93		3		8.93
$	9.31		218		5.3		9.31		208		9.31
$9.78 - $14.95			119		4.9		12.45		109		12.22
$16.8 - $21.9			171		9.1		20.35		32		19.74
			1,083		6.2	$	10.19		776	$	8.81

The Stock Plan also permits us to grant restricted shares and restricted units of our common stock to eligible employees, including officers, and our outside directors. Generally, these shares or units are nontransferable until vested and are subject to vesting requirements and/or forfeiture, as determined by our Compensation Committee or Board of Directors. The market value of these shares and units at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $6,357, $2,705 and $2,861 related to restricted shares was recognized during the years ended December 31, 2018, 2017, and 2016, respectively.

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:

	Units			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2018		671			7.83
Granted		226			19.17
Vested		(531	)		9.49
Forfeited		(9	)		11.48
Issued and unvested, December 31, 2018		357		$	12.14
Issued and expected to vest, December 31, 2018		357		$	12.14

As of December 31, 2018, there was $2,556 of unrecognized compensation expense related to unvested restricted stock awards and unvested restricted stock units that is expected to be recognized over a weighted average period of 2.2 years.

In connection with the vesting of restricted shares during the years ended December 31, 2018, 2017 and 2016, we purchased and immediately retired 171, 130 and 132 shares with aggregate values of $3,291, $1,240 and $784, respectively, in satisfaction of minimum tax withholding and exercise obligations.

Commencing in 2016, we granted performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period, from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Performance during the one-year period will be based on a one-year earnings per share or income before taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested. Upon grant of the PSUs, we recognize compensation expense related to these awards based on assumptions as to what percentage of each target will be achieved. The Company evaluates these target assumptions on a quarterly basis and adjusts compensation expense related to these awards, as appropriate.

Compensation cost of $6,717, $2,223 and $511 related to the PSUs was recognized during the years ended December 31, 2018, 2017 and 2016, respectively.

The following table summarizes PSU activity under the Stock Plan:

	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2018		576			6.76
Granted⁽¹⁾		124			20.90
Performance adjustment⁽²⁾		14			6.44
Vested		(47	)		7.55
Forfeited		(6	)		15.77
Issued and unvested, December 31, 2018		661		$	9.26
Issued and expected to vest, December 31, 2018		661		$	9.26

^1.

Grant activity for all PSU’s disclosed at target.

^2.

Reflects the performance adjustment based on actual performance measured at the end of the performance period.

In connection with the vesting of performance stock units during the year ended December 31, 2018, we purchased and immediately retired 20 shares with aggregate values of $301. No performance stock units vested in 2017 or 2016.

Share Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired in 2018 and 2017. During the year ended December 31, 2016 we purchased and retired 423 shares of common stock at an average price of $6.29 per share for a total cost of $2,660.

Transition Costs

12 Months Ended

Dec. 31, 2018

Transition Costs [Abstract]

Transition Costs

10.	TRANSITION COSTS

In January 2018, we announced the retirement of our President and CEO and our CFO and Chief Operating Officer. Stephen S. Tang, Ph.D., who served as Chairman of the Board of Directors (the “Board”), was appointed as the Company’s new President and CEO, effective as of April 1, 2018. Dr. Tang replaced Douglas A. Michels, who retired as President and CEO, and as a member of the Board, on March 31, 2018. In addition, Roberto Cuca was appointed as the Company’s new CFO, effective June 8, 2018. Mr. Cuca replaced Ronald H. Spair, our former CFO and Chief Operating Officer, who retired on that same date. Charges associated with these transitions were $9,602 during 2018 and are included in general and administrative expenses in the consolidated statement of income. These charges primarily reflect non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company’s new President and CEO.

Business Segment Information

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Business Segment Information

11.	BUSINESS SEGMENT INFORMATION:

Our business is comprised of two segments: Our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types, and medical devices used to remove benign skin lesions by cryotherapy or “freezing.” Our molecular collections systems or “DNAG” business consists of the manufacture and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the years ended December 31, 2018, 2017, and 2016, and asset information as of December 31, 2018 and 2017:

	Years Ended December 31,
	2018			2017			2016
Net revenues:
OSUR	$	85,635		$	91,965		$	95,984
DNAG		96,108			75,099			32,214
Total	$	181,743		$	167,064		$	128,198
Operating income (loss):
OSUR	$	(20,123	)	$	(2,706	)	$	15,606
DNAG		48,552			42,944			4,659
Total	$	28,429		$	40,238		$	20,265
Depreciation and amortization:
OSUR	$	3,755		$	3,170		$	2,751
DNAG		3,467			3,232			2,889
Total	$	7,222		$	6,402		$	5,640
Capital expenditures:
OSUR	$	4,893		$	2,752		$	2,145
DNAG		1,451			1,585			2,208
Total	$	6,344		$	4,337		$	4,353

	December 31,
	2018		2017
Total assets:
OSUR	$	190,178	$	192,352
DNAG		125,393		103,849
Total	$	315,571	$	296,201

The following table represents total long-lived assets by geographic area:

	December 31,
	2018		2017
United States	$	18,776	$	16,160
Canada		5,192		5,083
Other regions		331		129
	$	24,299	$	21,372

Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

12.	COMMITMENTS AND CONTINGENCIES:

Leases

We lease office space for our Canadian subsidiary, domestic warehouse facilities and smaller pieces of equipment under operating lease agreements. Future payments required under these non-cancelable leases are as follows:

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Rent expense for 2018, 2017 and 2016 was $1,461, $852, and $715, respectively.

Purchase Commitments

As of December 31, 2018, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:

2019		9,683
2020		402
2021		19
2022		19
2023		17
	$	10,140

Employment Agreements

Under terms of employment agreements with certain employees, which extend through 2021, we are required to pay each individual a base salary for continuing employment with us. The agreements require payments totaling $1,779, $1,779 and $980 in 2019, 2020 and 2021, respectively.

Litigation

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Retirement Plans

12 Months Ended

Dec. 31, 2018

Compensation And Retirement Disclosure [Abstract]

Retirement Plans

13.	RETIREMENT PLANS:

Substantially all of our U.S. employees are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4 per year. We contributed $721, $617 and $619 to the 401(k) Plan, net of forfeitures, in 2018, 2017, and 2016, respectively.

In addition to our 401(k) plan, we offer a nonqualified deferred compensation plan to permit eligible directors and highly compensated employees of the Company to defer receipt and taxation of their compensation each year. We also may make discretionary contributions to the accounts of the participating employees in any amount either in cash or stock. Participants in the plan may not purchase OraSure stock as an investment vehicle. As of December 31, 2018 and 2017, the value of the assets associated with this plan was $3,884 and $3,514, respectively, and is included in current assets and other assets in our consolidated balance sheets. Our obligation related to the deferred compensation plan is included in accrued expenses and other liabilities in our consolidated balance sheets. As of December 31, 2017 and 2016, our total obligation under this plan was $3,884 and $3,514, respectively.

Substantially all regular full-time Canadian employees are eligible to participate in the DNA Genotek Registered Retirement Savings Plan (the “RRSP”). The RRSP permits voluntary employee contributions to be excluded from an employee’s current taxable income and receive tax preferred treatment with Revenue Canada. The RRSP also provides for DNAG to match employee contributions up to $2 per year. We contributed $163, $145 and $134 to the RRSP in 2018, 2017, and 2016, respectively.

Quarterly Data

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Data

14.	QUARTERLY DATA (Unaudited):

The following tables summarize the quarterly results of operations for each of the quarters in 2018 and 2017. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein.

	2018 Results
	Three months ended
	March 31, 2018					June 30, 2018		September 30, 2018		December 31, 2018

Net revenues	$	41,987				$	43,625	$	45,885	$	50,246
Costs and expenses		42,485					38,067		35,028		37,734
Operating income (loss)		(498	)				5,558		10,857		12,512
Other income, net		412					736		510		1,629
Income (loss) before income taxes		(86	)				6,294		11,367		14,141
Income tax expense		2,033					2,173		3,271		3,843
Net income (loss)	$	(2,119	)			$	4,121	$	8,096	$	10,298
Earnings (loss) per share
Basic	$	(0.03	)			$	0.07	$	0.13	$	0.17
Diluted	$	(0.03	)			$	0.07	$	0.13	$	0.16
	2017 Results
	Three months ended
	March 31, 2017					June 30, 2017		September 30, 2017		December 31, 2017

Net revenues	$	32,546				$	40,176	$	42,314	$	52,028
Costs and expenses		16,675		⁽¹	⁾		33,289		34,995		41,867
Operating income		15,871		⁽¹	⁾		6,887		7,319		10,161
Other income, net		467					96		113		118
Income before income taxes		16,338					6,983		7,432		10,279
Income tax expense		3,897					1,555		1,669		2,963
Net income	$	12,441				$	5,428	$	5,763	$	7,316

Earnings per share
Basic	$	0.22				$	0.09	$	0.10	$	0.12	⁽²	⁾
Diluted	$	0.21				$	0.09	$	0.09	$	0.12	⁽²	⁾

⁽¹⁾ Includes a $12,500 gain associated with the settlement of our litigation with Ancestry.com DNA LLC and its contract manufacturer, which was recorded as a reduction of operating expenses in the indicated period.

⁽²⁾ The summation of the quarterly amounts may not equal the year-end amounts as included in the consolidated financial statements due to the use of weighted-average shares for each period.

Subsequent Events

12 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

Subsequent Events

15.	SUBSEQUENT EVENTS:

On January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of CoreBiome, Inc. (“CoreBiome”), pursuant to the terms of a Merger Agreement, dated January 3, 2019. CoreBiome is a Minnesota-based early-stage microbiome laboratory services provider that accelerates research and discovery for customers in the pharmaceutical, agricultural, and research communities. These services provide optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics.

Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis NV (“Novosanis”), pursuant to a Share Purchase Agreement, dated January 3, 2019. Novosanis is a Belgian company founded as a spinoff company from the University of Antwerp in 2013. Novosanis is an early commercial-stage producer and distributor of urine sample collection devices targeted primarily at the liquid biopsy, sexually transmitted infection screening market. Novosanis’ primary product is Colli-Pee, an easy to use device designed for the standardized collection of first-void urine which can be used in the privacy of the user’s home or in a clinic. The initial commercial application of this product is for liquid biopsy in the prostate and bladder cancer markets. Product validation and clinical trials are also under way with various sexually transmitted infection test manufacturers.

The initial aggregate purchase price for both of these transaction approximated $12,014, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, pursuant to indemnification obligations under each agreement noted above. Both agreements include contingent payments to be paid based on the future performance of each company through a specified period of time as defined under the agreements.

Through December 31, 2018, we incurred a total of $1,235 million of acquisition related costs, including investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of income for the year ended December 31, 2018.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Supplemental Cash Flow Information

In 2018, 2017 and 2016, we paid income taxes of $17,126, $4,309 and $1,123, respectively.

As of December 31, 2018, 2017 and 2016, we had accruals for purchases of property and equipment of $964, $449 and $302, respectively.

Investments

The following is a summary of our available-for-sale securities as of December 31, 2018 and 2017:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
December 31, 2017
Guaranteed investment certificates	$	22,261	$	—	$	—		$	22,261
Corporate bonds		82,010		—		(553	)		81,457
Total available-for-sale securities	$	104,271	$	—	$	(553	)	$	103,718
At December 31, 2018, maturities of our available- for-sale securities were as follows:
Less than one year	$	68,702	$	—	$	(568	)	$	68,134
Greater than one year	$	45,101	$	—	$	(349	)	$	44,752

Accounts Receivable

Inventories

Property and Equipment

Intangible Assets

Impairment of Long-Lived Assets

Goodwill

Revenue

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

Deferred Revenue

Product Sales

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Arrangements with Multiple-performance Obligations

Other Revenues

Financing and Payment

For certain products or services and customer types, we may require payment before the products are delivered or services are rendered to the customer.

Practical Expedients and Exemptions

Practical expedients and exemptions. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Twelve Months Ended December 31,
	2018		2017		2016
OraQuick®	$	53,851	$	60,558	$	47,134
Oragene®		75,850		69,184		29,454
Intercept®		7,709		8,125		8,351
Histofreezer®		8,983		10,312		11,628
Other products		19,035		13,809		10,357
Net product revenues		165,428		161,988		106,924

Royalty income		9,653		-		-
AbbVie exclusivity		-		-		18,951
BARDA funding		4,951		4,387		2,323
Charitable support reimbursement		1,711		689		-
Other revenues		16,315		5,076		21,274

Net revenues	$	181,743	$	167,064	$	128,198

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	December 31,
	2018		2017		2016
United States	$	136,847	$	121,458	$	99,758
Europe		11,062		11,827		11,646
Other regions		33,834		33,779		16,794
	$	181,743	$	167,064	$	128,198

Customer and Vendor Concentrations

Research and Development

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2018, 2017, and 2016, we incurred $763, $717, and $626, respectively, in advertising expenses.

Stock-Based Compensation

Income Taxes

Foreign Currency Translation

Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Year ended December 31,
	2018		2017			2016
Net income	$	20,396		$	30,948	$	19,720
Weighted average shares of common stock outstanding:
Basic		61,112			59,050		55,615
Dilutive effect of stock options, restricted stock, and performance stock units		1,420			1,974		898
Diluted		62,532			61,024		56,513
Earnings per share:
Basic	$	0.33		$	0.52	$	0.35
Diluted	$	0.33		$	0.51	$	0.35

Accumulated Other Comprehensive Loss

Fair Value of Financial Instruments

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 1 instruments as of December 31, 2018 and 2017.

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of December 31, 2018 and 2017:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2018
Guaranteed investment certificates	$	23,096	$	—	$	—		$	23,096
Corporate bonds		90,707		—		(917	)		89,790
Total available-for-sale securities	$	113,803	$	—	$	(917	)	$	112,886
December 31, 2017
Guaranteed investment certificates	$	22,261	$	—	$	—		$	22,261
Corporate bonds		82,010		—		(553	)		81,457
Total available-for-sale securities	$	104,271	$	—	$	(553	)	$	103,718
At December 31, 2018, maturities of our available- for-sale securities were as follows:
Less than one year	$	68,702	$	—	$	(568	)	$	68,134
Greater than one year	$	45,101	$	—	$	(349	)	$	44,752

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Twelve Months Ended December 31,
	2018		2017		2016
OraQuick®	$	53,851	$	60,558	$	47,134
Oragene®		75,850		69,184		29,454
Intercept®		7,709		8,125		8,351
Histofreezer®		8,983		10,312		11,628
Other products		19,035		13,809		10,357
Net product revenues		165,428		161,988		106,924

Royalty income		9,653		-		-
AbbVie exclusivity		-		-		18,951
BARDA funding		4,951		4,387		2,323
Charitable support reimbursement		1,711		689		-
Other revenues		16,315		5,076		21,274

Net revenues	$	181,743	$	167,064	$	128,198

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	December 31,
	2018		2017		2016
United States	$	136,847	$	121,458	$	99,758
Europe		11,062		11,827		11,646
Other regions		33,834		33,779		16,794
	$	181,743	$	167,064	$	128,198

Computations of Basic and Diluted Earnings Per Share

The computations of basic and diluted earnings per share are as follows:

	Year ended December 31,
	2018		2017			2016
Net income	$	20,396		$	30,948	$	19,720
Weighted average shares of common stock outstanding:
Basic		61,112			59,050		55,615
Dilutive effect of stock options, restricted stock, and performance stock units		1,420			1,974		898
Diluted		62,532			61,024		56,513
Earnings per share:
Basic	$	0.33		$	0.52	$	0.35
Diluted	$	0.33		$	0.51	$	0.35

ASU 2014-09 [Member]

Summary of Impact of New Revenue Standard Adjustment on Opening Balance Sheet

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)

Inventories (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Schedule of Inventories

	December 31,
	2018		2017
Raw materials	$	14,092	$	10,299
Work in process		544		199
Finished goods		8,252		8,845
	$	22,888	$	19,343

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment

	December 31,
	2018			2017
Land	$	1,118		$	1,118
Buildings and improvements		22,480			20,726
Machinery and equipment		29,017			26,685
Computer equipment and software		9,632			9,131
Furniture and fixtures		2,681			2,194
Construction in progress		2,168			897
		67,096			60,751
Less accumulated depreciation		(42,797	)		(39,379	)
	$	24,299		$	21,372

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Changes in Goodwill

The changes in goodwill are as follows:

	December 31,
	2018			2017
Balance as of January 1	$	20,083		$	18,793
Change related to foreign currency translation		(1,562	)		1,290
Balance as of December 31	$	18,521		$	20,083

Summary of Intangible Assets

Intangible assets consist of the following:

			December 31, 2018
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,186	$	(6,532	)	$	2,654
Patents and product rights		10		5,400		(4,708	)		692
Acquired technology		7		7,135		(7,135	)		-
Tradename		15		3,521		(1,730	)		1,791
			$	25,242	$	(20,105	)	$	5,137

			December 31, 2017
	Amortization Period (Years)		Gross		Accumulated Amortization			Net
Customer list		10	$	9,960	$	(6,112	)	$	3,838
Patents and product rights		10		5,400		(4,258	)		1,142
Acquired technology		7		7,737		(6,690	)		1,047
Tradename		15		3,818		(1,622	)		2,196
			$	26,915	$	(18,692	)	$	8,223

Summary of Patents and Products Rights

Patents and products rights are made up of the following:

	December 31,
	2018			2017
HIV-related	$	900		$	900
HCV-related		4,500			4,500
		5,400			5,400
Less accumulated amortization		(4,708	)		(4,258	)
	$	692		$	1,142

Summary of Amortization Expense

Amortization expense for each of the five succeeding fiscal years and beyond is estimated as follows:

2019		1,617
2020		1,409
2021		1,165
2022		245
2023		245
Beyond		456
	$	5,137

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

	December 31,
	2018		2017
Payroll and related benefits	$	8,926	$	9,265
Professional fees		1,541		1,064
Income taxes payable		1,447		6,469
Royalties		—		845
Other		1,947		3,052
	$	13,861	$	20,695

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Tax Expense (Benefit)

Income before income tax expense consists of the following:

	Years Ended December 31,
	2018			2017		2016
United States	$	(11,728	)	$	2,270	$	18,492
Canada		43,444			38,762		1,831
	$	31,716		$	41,032	$	20,323

Components of Income Tax Expense (Benefit)

The components of income tax expense are as follows:

	Years Ended December 31,
	2018			2017			2016
Current
Federal	$	—		$	—		$	—
State		155			—			250
Canada		12,084			10,733			882
		12,239			10,733			1,132
Deferred
Federal		9,200			10,297			6,508
State		1,011			(827	)		569
Canada		(919	)		(649	)		(529	)
		9,292			8,821			6,548
Decrease in valuation allowance		(10,211	)		(9,470	)		(7,077	)
		(919	)		(649	)		(529	)
Total income tax expense	$	11,320		$	10,084		$	603

Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate

A reconciliation of the statutory United States federal income tax rate to our effective tax rate for each of the years ended December 31, 2018, 2017, and 2016 is as follows:

	2018				2017				2016
Statutory U.S. federal income tax rate		21.0		%		34.0		%		34.0		%
Deemed repatriation tax		10.9				7.8				—
GILTI tax		22.2				—				—
Statutory rate change, deferred tax impact		—				29.4				—
Nondeductible executive compensation		4.8				—				—
Impact of share-based payment awards		0.6				(16.0	)			—
Tax effect of Canadian items		6.8				(8.3	)			(1.9	)
State income taxes, net of federal benefit		2.8				(1.1	)			2.0
Nondeductible expenses and other		(1.2	)			1.9				3.7
Change in valuation allowance, federal and state		(32.2	)			(23.1	)			(34.8	)
Effective tax rate		35.7		%		24.6		%		3.0		%

Components of Total Deferred Tax Assets (Liabilities)

Significant components of our deferred tax assets (liabilities) as of December 31, 2018 and 2017 are as follows:

	2018			2017
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	10,812		$	15,338
Inventories		1,005			1,179
Capitalized research and development costs		1,697			2,402
Accruals and reserves currently not deductible		3,767			3,103
Acquired intangible assets		(1,153	)		(1,825	)
Depreciation and amortization		(1,082	)		(621	)
Stock-based compensation		1,248			976
Tax credit carryforwards		1,819			6,722
Net deferred tax asset		18,113			27,274
Valuation allowance		(19,014	)		(29,225	)
Net deferred tax liability	$	(901	)	$	(1,951	)

Expiry Details of Federal Net Operating Losses Carryforwards

Our Federal NOL carryforwards expire as follows:

Year of Expiration	NOLs
2030 - 2034	$	36,100
2035 - 2037		11,260
	$	47,360

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of our unrecognized tax benefits is as follows:

	2018			2017			2016
Balance as of January 1	$	1,663		$	2,084		$	2,088
Additions for tax positions of prior periods		44			—			-
Reductions for tax positions of prior periods		(31	)		(421	)		(4	)
Balance as of December 31	$	1,676		$	1,663		$	2,084

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2018

Weighted-Average Assumptions for Fair Value Measurement

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Years Ended December 31,
Black-Scholes Option Valuation Assumptions	2018			2017			2016
Risk-free interest rate⁽¹⁾		2.60	%		2.22	%		1.76	%
Expected dividend yield		—			—			—
Expected stock price volatility⁽²⁾		43	%		43	%		46	%
Expected life of stock options (in years)⁽²⁾		6			7			7

⁽¹⁾	Based on the constant maturity interest rate of U.S. Treasury securities whose term is consistent with the expected life of our stock options.

⁽²⁾	Based upon historical experience.

Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options

Compensation expense recognized in the financial statements related to stock options was as follows:

	Years Ended December 31,
	2018			2017			2016
Total compensation cost during the year	$	2,163		$	2,045		$	2,691
Amounts capitalized into inventory during the year		(420	)		(371	)		(270	)
Amounts recognized in cost of products sold for amounts previously capitalized		396			276			212
Amounts charged against income	$	2,139		$	1,950		$	2,633

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity under the Stock Plan:

	Options			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding on January 1, 2018		1,201			8.04
Granted		171			20.35
Exercised		(227	)		7.47
Expired		(38	)		6.05
Forfeited		(24	)		7.53
Outstanding on December 31, 2018		1,083		$	10.19		6.2	$	3,047
Vested or expected to vest as of December 31, 2018		1,083		$	10.19		6.2	$	3,047
Exercisable on December 31, 2018		776		$	8.81		5.3	$	2,434

Schedule of Currently Outstanding and Exercisable Stock Options

The following table summarizes information about stock options outstanding as of December 31, 2018:

Options outstanding								Options exercisable
Range of exercise prices		Number Outstanding		Weighted- Average Remaining Contractual Term (in years)		Weighted- Average Exercise Price Per Share		Number Exercisable		Weighted- Average Exercise Price Per Share
$	5.37		121		6.9	$	5.37		64	$	5.37
$	5.47		3		6.7		5.47		2		5.47
$	5.71		120		4.4		5.71		120		5.71
$5.79 - $7.28			114		5.4		7.06		112		7.06
$7.33 - $8.63			74		3.2		8.30		73		8.32
$	8.87		137		8.0		8.87		53		8.87
$	8.93		6		8.0		8.93		3		8.93
$	9.31		218		5.3		9.31		208		9.31
$9.78 - $14.95			119		4.9		12.45		109		12.22
$16.8 - $21.9			171		9.1		20.35		32		19.74
			1,083		6.2	$	10.19		776	$	8.81

Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan

The following table summarizes restricted stock award and restricted stock units activity under the Stock Plan:

	Units			Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2018		671			7.83
Granted		226			19.17
Vested		(531	)		9.49
Forfeited		(9	)		11.48
Issued and unvested, December 31, 2018		357		$	12.14
Issued and expected to vest, December 31, 2018		357		$	12.14

Performance Based Restricted Stock Unit [Member]

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes PSU activity under the Stock Plan:

	Units			Weighted- Average Grant Date Fair Value
Issued and unvested, January 1, 2018		576			6.76
Granted⁽¹⁾		124			20.90
Performance adjustment⁽²⁾		14			6.44
Vested		(47	)		7.55
Forfeited		(6	)		15.77
Issued and unvested, December 31, 2018		661		$	9.26
Issued and expected to vest, December 31, 2018		661		$	9.26

^1.

Grant activity for all PSU’s disclosed at target.

^2.

Reflects the performance adjustment based on actual performance measured at the end of the performance period.

Business Segment Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the years ended December 31, 2018, 2017, and 2016, and asset information as of December 31, 2018 and 2017:

	Years Ended December 31,
	2018			2017			2016
Net revenues:
OSUR	$	85,635		$	91,965		$	95,984
DNAG		96,108			75,099			32,214
Total	$	181,743		$	167,064		$	128,198
Operating income (loss):
OSUR	$	(20,123	)	$	(2,706	)	$	15,606
DNAG		48,552			42,944			4,659
Total	$	28,429		$	40,238		$	20,265
Depreciation and amortization:
OSUR	$	3,755		$	3,170		$	2,751
DNAG		3,467			3,232			2,889
Total	$	7,222		$	6,402		$	5,640
Capital expenditures:
OSUR	$	4,893		$	2,752		$	2,145
DNAG		1,451			1,585			2,208
Total	$	6,344		$	4,337		$	4,353

	December 31,
	2018		2017
Total assets:
OSUR	$	190,178	$	192,352
DNAG		125,393		103,849
Total	$	315,571	$	296,201

Presentation of Total Long-Lived Assets by Geographic Area

The following table represents total long-lived assets by geographic area:

	December 31,
	2018		2017
United States	$	18,776	$	16,160
Canada		5,192		5,083
Other regions		331		129
	$	24,299	$	21,372

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Schedule for Future Minimum Lease Payments under Operating Lease Agreements

2019	$	903
2020		902
2021		877
2022		850
2023		506
Thereafter		737
	$	4,775

Schedule of Outstanding Non-cancelable Purchase Commitments

As of December 31, 2018, we had outstanding non-cancelable purchase commitments related to inventory, supplies, capital expenditures, and other goods or services as follows:

2019		9,683
2020		402
2021		19
2022		19
2023		17
	$	10,140

Quarterly Data (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Summary of Quarterly Results of Operations

	2018 Results
	Three months ended
	March 31, 2018					June 30, 2018		September 30, 2018		December 31, 2018

Net revenues	$	41,987				$	43,625	$	45,885	$	50,246
Costs and expenses		42,485					38,067		35,028		37,734
Operating income (loss)		(498	)				5,558		10,857		12,512
Other income, net		412					736		510		1,629
Income (loss) before income taxes		(86	)				6,294		11,367		14,141
Income tax expense		2,033					2,173		3,271		3,843
Net income (loss)	$	(2,119	)			$	4,121	$	8,096	$	10,298
Earnings (loss) per share
Basic	$	(0.03	)			$	0.07	$	0.13	$	0.17
Diluted	$	(0.03	)			$	0.07	$	0.13	$	0.16
	2017 Results
	Three months ended
	March 31, 2017					June 30, 2017		September 30, 2017		December 31, 2017

Net revenues	$	32,546				$	40,176	$	42,314	$	52,028
Costs and expenses		16,675		⁽¹	⁾		33,289		34,995		41,867
Operating income		15,871		⁽¹	⁾		6,887		7,319		10,161
Other income, net		467					96		113		118
Income before income taxes		16,338					6,983		7,432		10,279
Income tax expense		3,897					1,555		1,669		2,963
Net income	$	12,441				$	5,428	$	5,763	$	7,316

Earnings per share
Basic	$	0.22				$	0.09	$	0.10	$	0.12	⁽²	⁾
Diluted	$	0.21				$	0.09	$	0.09	$	0.12	⁽²	⁾

⁽²⁾ The summation of the quarterly amounts may not equal the year-end amounts as included in the consolidated financial statements due to the use of weighted-average shares for each period.

The Company - Additional Information (Detail)	12 Months Ended
The Company - Additional Information (Detail)	Dec. 31, 2018 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands		1 Months Ended					12 Months Ended
	Jun. 12, 2015 USD ($)	Jul. 31, 2017 USD ($)	Jun. 30, 2017 USD ($) Country	May 31, 2017 USD ($)	Aug. 31, 2016 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2018 USD ($) Supplier shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares	Jan. 01, 2018 USD ($) PerformanceObligation
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income taxes paid							$ 17,126,000	$ 4,309,000	$ 1,123,000
Increase or decrease in allowance for doubtful accounts							(27,000)	172,000	40,000
Write-offs against allowance for doubtful accounts							11,000	200,000	369,000
Accruals for purchases of property and equipment							964,000	449,000	302,000
Accumulated deficit							(99,189,000)	(119,510,000)
Revenue recognized							0	0	18,951,000
Maximum value of grant revenue from clinical and regulatory activities	$ 10,400,000				$ 16,600,000
Period of grant	3 years				6 years
Grant expiration period	2018-10
Amended grant expiration period	Dec. 31, 2019
Initial grant revenue from clinical and regulatory activities	$ 1,800,000				$ 7,000,000
Remaining grant revenue from clinical and regulatory activities	$ 8,600,000				$ 9,600,000
Additional contract revenue from clinical and regulatory activities		$ 1,330,000		$ 2,600,000		$ 7,200,000
Contract revenues from clinical and regulatory activities							2,988,000	1,999,000	1,707,000
Deferred revenue							$ 3,521,000	1,314,000
Contract with customer payment terms, description							Payment terms differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.
Reserve for sales return and allowances							$ 191,000	217,000
Advertising expenses							763,000	717,000	626,000
Net foreign exchange (losses) gains							831,000	(1,442,000)	$ (607,000)
Accumulated foreign currency adjustments included in other comprehensive loss amounted							17,789,000	9,787,000
Unrealized loss on marketable securities							917,000	553,000
Cash and cash equivalents							88,438,000	71,029,000
Fair value of plan assets							3,884,000	3,514,000
Restricted cash								1,840,000
Long-term Contract [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue							1,464,000	269,000
ASU 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit										$ (119,585,000)
Deferred revenue										1,389,000
ASU 2014-09 [Member] \| Change in Revenue Recognition [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit										(75,000)
Deferred revenue										$ 75,000
Ora Quick HIV Self Test [Member] \| Bill & Melinda Gates Foundation [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Charitable support agreement term			4 years
Number of countries in which products are sold \| Country			50
Maximum amount of funding over the agreement period			$ 20,000,000
Funding received per year			$ 6,000,000
Support payments recognized in product revenue							4,429,000	1,047,000
Support payments recognized in other revenue							$ 1,711,000	689,000
Charitable support agreement commencement date							2017-06
Drug Testing Kit Sales [Member] \| ASU 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of performance obligations \| PerformanceObligation										2
Drug Testing Kit Sales [Member] \| ASU 2014-09 [Member] \| Change in Revenue Recognition [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accumulated deficit										$ 75,000
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents							$ 21,631,000	$ 40,760,000
Common Stock Options Unvested Restricted Stock and Unvested Performance Units [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of anti-dilutive securities excluded from EPS computation \| shares							291	180	2,546
Up Front Payment Arrangement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred revenue							$ 2,057,000	$ 1,045,000
AbbVie [Member] \| Collaborative Arrangement Co-promotion [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expiration date of rights agreement							Dec. 31, 2016
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk							7.00%	37.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk							24.00%	25.00%
Customer One [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of concentration risk									15.00%
Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract revenues from clinical and regulatory activities							$ 1,963,000	$ 2,388,000	$ 616,000
Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Certificates of deposit maturity date								Jan. 22, 2018
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets							7 years
Contract with customer payment terms							30 days
Minimum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit								0.89%
Restricted cash							$ 0
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Useful life of Intangible assets							15 years
Contract with customer payment terms							120 days
Sales commissions amortization period							1 year
Maximum [Member] \| ASU 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of total assets recognized as right-of-use assets							2.00%
Percentage of total liabilities recognized as lease liabilities							16.00%
Maximum [Member] \| Certificates of Deposit [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest rate on certificates of deposit								1.03%
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets							10 years
DNA Genotek [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of third-party suppliers to manufacture DNAG's products \| Supplier							2
Ancestry.com DNA LLC [Member] \| Litigation Settlement Agreement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Royalty income							$ 9,653,000

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 113,803	$ 104,271
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(917)	(553)
Fair Value	112,886	103,718
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	23,096	22,261
Gross Unrealized Gains	0	0
Fair Value	23,096	22,261
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	90,707	82,010
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(917)	(553)
Fair Value	89,790	$ 81,457
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	68,702
Gross Unrealized Gains	0
Gross Unrealized Losses	(568)
Fair Value	68,134
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	45,101
Gross Unrealized Gains	0
Gross Unrealized Losses	(349)
Fair Value	$ 44,752

Summary of Significant Accounting Policies - Summary of Impact of New Revenue Standard Adjustment on Opening Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
CURRENT LIABILITIES:
Deferred revenue	$ 3,521		$ 1,314
STOCKHOLDERS' EQUITY
Accumulated deficit	$ (99,189)		$ (119,510)
ASU 2014-09 [Member]
CURRENT LIABILITIES:
Deferred revenue		$ 1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,585)
New Revenue Standard Adjustment [Member] \| ASU 2014-09 [Member]
CURRENT LIABILITIES:
Deferred revenue		75
STOCKHOLDERS' EQUITY
Accumulated deficit		$ (75)

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation Of Revenue [Line Items]
Net revenues	$ 181,743	$ 167,064	$ 128,198
Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	165,428	161,988	106,924
Product Revenues [Member] \| OraQuick [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	53,851	60,558	47,134
Product Revenues [Member] \| Oragene [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	75,850	69,184	29,454
Product Revenues [Member] \| Intercept [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	7,709	8,125	8,351
Product Revenues [Member] \| Histofreezer [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	8,983	10,312	11,628
Product Revenues [Member] \| Other Products [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	19,035	13,809	10,357
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	16,315	5,076	21,274
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	9,653
Other [Member] \| AbbVie Exlcusivity [Member]
Disaggregation Of Revenue [Line Items]
Net revenues			18,951
Other [Member] \| BARDA Funding [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	4,951	4,387	$ 2,323
Other [Member] \| Charitable Support Reimbursement [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 1,711	$ 689

Summary of Significant Accounting Policies - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disaggregation Of Revenue [Line Items]
Net revenues	$ 181,743	$ 167,064	$ 128,198
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	136,847	121,458	99,758
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,062	11,827	11,646
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 33,834	$ 33,779	$ 16,794

Summary of Significant Accounting Policies - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Net income	$ 10,298	$ 8,096	$ 4,121	$ (2,119)	$ 7,316	$ 5,763	$ 5,428	$ 12,441	$ 20,396	$ 30,948	$ 19,720
SHARES USED IN COMPUTING EARNINGS PER SHARE:
BASIC									61,112	59,050	55,615
Dilutive effect of stock options, restricted stock, and performance stock units									1,420	1,974	898
Diluted									62,532	61,024	56,513
BASIC	$ 0.17	$ 0.13	$ 0.07	$ (0.03)	$ 0.12	$ 0.10	$ 0.09	$ 0.22	$ 0.33	$ 0.52	$ 0.35
DILUTED	$ 0.16	$ 0.13	$ 0.07	$ (0.03)	$ 0.12	$ 0.09	$ 0.09	$ 0.21	$ 0.33	$ 0.51	$ 0.35

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory Net [Abstract]
Raw materials	$ 14,092	$ 10,299
Work in process	544	199
Finished goods	8,252	8,845
Inventories	$ 22,888	$ 19,343

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 67,096	$ 60,751
Less accumulated depreciation	(42,797)	(39,379)
Property plant and equipment Net	24,299	21,372
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	1,118	1,118
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	22,480	20,726
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	29,017	26,685
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	9,632	9,131
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	2,681	2,194
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment Gross	$ 2,168	$ 897

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 3,828	$ 3,434	$ 3,149

Goodwill and Other Intangible Assets - Schedule of Changes in Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill Roll Forward
Beginning Balance	$ 20,083	$ 18,793
Change related to foreign currency translation	(1,562)	1,290
Ending Balance	$ 18,521	$ 20,083

Goodwill and Other Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 25,242	$ 26,915
Intangible Assets, Accumulated Amortization	(20,105)	(18,692)
Intangible Assets, Net	$ 5,137	$ 8,223
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 9,186	$ 9,960
Intangible Assets, Accumulated Amortization	(6,532)	(6,112)
Intangible Assets, Net	$ 2,654	$ 3,838
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	10 years	10 years
Intangible Assets, Gross	$ 5,400	$ 5,400
Intangible Assets, Accumulated Amortization	(4,708)	(4,258)
Intangible Assets, Net	$ 692	$ 1,142
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	7 years	7 years
Intangible Assets, Gross	$ 7,135	$ 7,737
Intangible Assets, Accumulated Amortization	$ (7,135)	(6,690)
Intangible Assets, Net		$ 1,047
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Amortization Period (Years)	15 years	15 years
Intangible Assets, Gross	$ 3,521	$ 3,818
Intangible Assets, Accumulated Amortization	(1,730)	(1,622)
Intangible Assets, Net	$ 1,791	$ 2,196

Goodwill and Other Intangible Assets - Summary of Patents and Products Rights (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	$ 25,242	$ 26,915
Less accumulated amortization	(20,105)	(18,692)
Patent and products right, Net	5,137	8,223
HIV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	900	900
HCV-Related [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	4,500	4,500
Patents and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Patent and products gross amount	5,400	5,400
Less accumulated amortization	(4,708)	(4,258)
Patent and products right, Net	$ 692	$ 1,142

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,623	$ 2,641	$ 2,538

Goodwill and Other Intangible Assets - Summary of Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2019	$ 1,617
2020	1,409
2021	1,165
2022	245
2023	245
Beyond	456
Intangible Assets, Net	$ 5,137	$ 8,223

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 8,926	$ 9,265
Professional fees	1,541	1,064
Income taxes payable	1,447	6,469
Royalties		845
Other	1,947	3,052
Accrued Expenses, Total	$ 13,861	$ 20,695

Credit Facility - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 10,000,000
Line of credit facility, collateral	Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
Borrowings	$ 0	$ 0
Unused capacity commitment fee	0.375%
Maturity date of credit facility	Sep. 30, 2019
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Current borrowing capacity	$ 2,500,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	110.00%
Line of Credit [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Line of credit, interest rate	2.50%

Income Taxes - Schedule of Income (Loss) Before Income Tax Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest [Abstract]
United States									$ (11,728)	$ 2,270	$ 18,492
Canada									43,444	38,762	1,831
Income before income taxes	$ 14,141	$ 11,367	$ 6,294	$ (86)	$ 10,279	$ 7,432	$ 6,983	$ 16,338	$ 31,716	$ 41,032	$ 20,323

Income Taxes - Components of Income Tax Expense (Benefit) (Detail) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current
Federal									$ 0	$ 0	$ 0
State									155,000		250,000
Canada									12,084,000	10,733,000	882,000
Total current income tax expense (benefit)									12,239,000	10,733,000	1,132,000
Deferred
Federal									9,200,000	10,297,000	6,508,000
State									1,011,000	(827,000)	569,000
Canada									(919,000)	(649,000)	(529,000)
Total deferred income tax expense (benefit)									9,292,000	8,821,000	6,548,000
Decrease in valuation allowance	$ (11,273,000)								(10,211,000)	(9,470,000)	(7,077,000)
Deferred income taxes									(919,000)	(649,000)	(529,000)
Total income tax expense	$ 3,843,000	$ 3,271,000	$ 2,173,000	$ 2,033,000	$ 2,963,000	$ 1,669,000	$ 1,555,000	$ 3,897,000	$ 11,320,000	$ 10,084,000	$ 603,000

Income Taxes - Additional Information (Detail) - USD ($)		3 Months Ended	12 Months Ended
	Jan. 01, 2017	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Foreign income tax expense			$ 11,165,000	$ 10,084,000	$ 353,000
Effective income tax rate			21.00%	34.00%	34.00%
Final one-time transitioned income			$ (919,000)	$ (649,000)	$ (529,000)
Decrease in deferred tax assets		$ 11,273,000	11,273,000
Decrease in valuation allowance		(11,273,000)	(10,211,000)	(9,470,000)	(7,077,000)
U.S. federal income tax benefits			0	0	0
Increase valuation allowance associated with tax benefit	$ 3,391,000
Gross unrecognized tax benefits		1,676,000	1,676,000	$ 1,663,000	$ 2,084,000	$ 2,088,000
Accounting Standards Update 2016-09 [Member]
Income Taxes [Line Items]
Cumulative effect of retained earnings	$ 3,391,000
2017 Federal Tax Return [Member]
Income Taxes [Line Items]
Final one-time transitioned income			17,724,000
Foreign tax credits		$ 0	$ 0

Income Taxes - Reconciliation of Statutory United States Federal Income Tax Rate to Domestic Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Statutory U.S. federal income tax rate	21.00%	34.00%	34.00%
Deemed repatriation tax	10.90%	7.80%
GILTI tax	22.20%
Statutory rate change, deferred tax impact		29.40%
Nondeductible executive compensation	4.80%
Impact of share-based payment awards	0.60%	(16.00%)
Tax effect of Canadian items	6.80%	(8.30%)	(1.90%)
State income taxes, net of federal benefit	2.80%	(1.10%)	2.00%
Nondeductible expenses and other	(1.20%)	1.90%	3.70%
Change in valuation allowance, federal and state	(32.20%)	(23.10%)	(34.80%)
Effective tax rate	35.70%	24.60%	3.00%

Income Taxes - Components of Total Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 10,812	$ 15,338
Inventories	1,005	1,179
Capitalized research and development costs	1,697	2,402
Accruals and reserves currently not deductible	3,767	3,103
Acquired intangible assets	(1,153)	(1,825)
Depreciation and amortization	(1,082)	(621)
Stock-based compensation	1,248	976
Tax credit carryforwards	1,819	6,722
Net deferred tax asset	18,113	27,274
Valuation allowance	(19,014)	(29,225)
Net deferred tax liability	$ (901)	$ (1,951)

Income Taxes - Expiry Details of Federal Net Operating Losses Carryforwards (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 47,360
2030 - 2034 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	36,100
2035 - 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 11,260

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Balance as of January 1	$ 1,663	$ 2,084	$ 2,088
Additions for tax positions of prior periods	44
Reductions for tax positions of prior periods	(31)	(421)	(4)
Balance as of December 31	$ 1,676	$ 1,663	$ 2,084

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants under the Stock Plan	3,704,000
Amount share repurchase program of common shares				$ 25,000,000
Total cost of common stock purchased and retired	$ 3,592,000	$ 1,240,000	$ 3,444,000
Proceeds from exercise of stock options	1,701,000	31,675,000	2,656,000
Income tax benefit realized from stock option exercises during period	0	0	0
Total compensation cost	$ 15,237,000	$ 6,973,000	$ 6,063,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0	423,000
Average price of common stock			$ 6.29
Total cost of common stock purchased and retired			$ 2,660,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of the fair market value of a share granted as Stock plan price	75.00%
Granted exercise periods	10 years
Vesting period	4 years
Vesting of Options	Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years.
Weighted-average grant date fair value of stock options granted	$ 9.15	$ 4.71	$ 2.91
Aggregate intrinsic value of options exercised	$ 2,314,000	$ 35,631,000	$ 763,000
Unrecognized compensation expense related to unvested option awards	$ 1,677,000
Expected weighted-average period for recognition of compensation expense related to unvested awards	1 year 10 months 24 days
Proceeds from exercise of stock options	$ 1,701,000	31,675,000	2,656,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognition of compensation expense related to unvested awards	2 years 2 months 12 days
Total compensation cost	$ 6,357,000	$ 2,705,000	$ 2,861,000
Unrecognized compensation expense related to unvested restricted stock awards	$ 2,556,000
Vesting of restricted shares, withholding and exercise obligations	171,000	130,000	132,000
Restricted shares of common stock, aggregate values	$ 3,291,000	$ 1,240,000	$ 784,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	20,000
Total cost of common stock purchased and retired	$ 301,000
Total compensation cost	$ 6,717,000	$ 2,223,000	$ 511,000
Performance stock units vested	47,000	0	0

Stockholders' Equity - Weighted-Average Assumptions for Fair Value Measurement (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Risk-free interest rate	2.60%	2.22%	1.76%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	43.00%	43.00%	46.00%
Expected life of stock options (in years)	6 years	7 years	7 years

Stockholders' Equity - Schedule of Compensation Expense Recognized in Financial Statements Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]
Total compensation cost during the year	$ 2,163	$ 2,045	$ 2,691
Amounts capitalized into inventory during the year	(420)	(371)	(270)
Amounts recognized in cost of products sold for amounts previously capitalized	396	276	212
Amounts charged against income	$ 2,139	$ 1,950	$ 2,633

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options, Outstanding, Beginning Balance \| shares	1,201
Options, Granted \| shares	171
Options, Exercised \| shares	(227)
Options, Expired \| shares	(38)
Options, Forfeited \| shares	(24)
Options, Outstanding, Ending Balance \| shares	1,083
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance \| $ / shares	$ 8.04
Options, Vested or expected to vest \| shares	1,083
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	$ 20.35
Options, Exercisable \| shares	776
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	$ 7.47
Weighted-Average Exercise Price Per Share, Expired \| $ / shares	6.05
Weighted-Average Exercise Price Per Share, Forfeited \| $ / shares	7.53
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance \| $ / shares	10.19
Weighted-Average Exercise Price Per Share, Vested or expected to vest \| $ / shares	10.19
Weighted-Average Exercise Price Per Share, Exercisable \| $ / shares	$ 8.81
Weighted-Average Remaining Contractual Term, Outstanding	6 years 2 months 12 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 2 months 12 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding \| $	$ 3,047
Aggregate Intrinsic Value, Vested or expected to vest \| $	3,047
Aggregate Intrinsic Value, Exercisable \| $	$ 2,434

Stockholders' Equity - Schedule of Currently Outstanding and Exercisable Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding, Options outstanding \| shares	1,083
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 2 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 10.19
Number Exercisable, Options exercisable \| shares	776
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.81
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.37
Number Outstanding, Options outstanding \| shares	121
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.37
Number Exercisable, Options exercisable \| shares	64
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.37
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.47
Number Outstanding, Options outstanding \| shares	3
Weighted-Average Remaining Contractual Term (in years), Options outstanding	6 years 8 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.47
Number Exercisable, Options exercisable \| shares	2
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.47
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 5.71
Number Outstanding, Options outstanding \| shares	120
Weighted-Average Remaining Contractual Term (in years), Options outstanding	4 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 5.71
Number Exercisable, Options exercisable \| shares	120
Weighted-Average Exercise Price Per Share, Options exercisable	$ 5.71
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	5.79
Range of exercise prices, Upper Range Limit	$ 7.28
Number Outstanding, Options outstanding \| shares	114
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 4 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 7.06
Number Exercisable, Options exercisable \| shares	112
Weighted-Average Exercise Price Per Share, Options exercisable	$ 7.06
Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	7.33
Range of exercise prices, Upper Range Limit	$ 8.63
Number Outstanding, Options outstanding \| shares	74
Weighted-Average Remaining Contractual Term (in years), Options outstanding	3 years 2 months 12 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.30
Number Exercisable, Options exercisable \| shares	73
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.32
Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 8.87
Number Outstanding, Options outstanding \| shares	137
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.87
Number Exercisable, Options exercisable \| shares	53
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.87
Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 8.93
Number Outstanding, Options outstanding \| shares	6
Weighted-Average Remaining Contractual Term (in years), Options outstanding	8 years
Weighted-Average Exercise Price Per Share, Options outstanding	$ 8.93
Number Exercisable, Options exercisable \| shares	3
Weighted-Average Exercise Price Per Share, Options exercisable	$ 8.93
Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Upper Range Limit	$ 9.31
Number Outstanding, Options outstanding \| shares	218
Weighted-Average Remaining Contractual Term (in years), Options outstanding	5 years 3 months 18 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 9.31
Number Exercisable, Options exercisable \| shares	208
Weighted-Average Exercise Price Per Share, Options exercisable	$ 9.31
Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	9.78
Range of exercise prices, Upper Range Limit	$ 14.95
Number Outstanding, Options outstanding \| shares	119
Weighted-Average Remaining Contractual Term (in years), Options outstanding	4 years 10 months 24 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 12.45
Number Exercisable, Options exercisable \| shares	109
Weighted-Average Exercise Price Per Share, Options exercisable	$ 12.22
Range Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Lower Range Limit	16.8
Range of exercise prices, Upper Range Limit	$ 21.9
Number Outstanding, Options outstanding \| shares	171
Weighted-Average Remaining Contractual Term (in years), Options outstanding	9 years 1 month 6 days
Weighted-Average Exercise Price Per Share, Options outstanding	$ 20.35
Number Exercisable, Options exercisable \| shares	32
Weighted-Average Exercise Price Per Share, Options exercisable	$ 19.74

Stockholders' Equity - Summary of Restricted Stock Award and Restricted Stock Units Activity Under Stock Plan (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance \| shares	671
Shares, Granted \| shares	226
Shares, Vested \| shares	(531)
Shares, Forfeited \| shares	(9)
Shares, Issued and unvested, Ending Balance \| shares	357
Shares, Issued and expected to vest \| shares	357
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance \| $ / shares	$ 7.83
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	19.17
Weighted-Average Grant Date Fair Value, Vested \| $ / shares	9.49
Weighted-Average Grant Date Fair Value, Forfeited \| $ / shares	11.48
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance \| $ / shares	12.14
Weighted-Average Grant Date Fair Value, Issued and expected to vest \| $ / shares	$ 12.14

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	576,000
Shares, Granted	124,000
Performance adjustment	14,000
Shares, Vested	(47,000)	0	0
Shares, Forfeited	(6,000)
Shares, Issued and unvested, Ending Balance	661,000	576,000
Shares, Issued and expected to vest	661,000
Weighted-Average Grant Date Fair Value, Issued and unvested, Beginning Balance	$ 6.76
Weighted-Average Grant Date Fair Value, Granted	20.90
Weighted-Average Grant Date Fair Value, Performance adjustment	6.44
Weighted-Average Grant Date Fair Value, Vested	7.55
Weighted-Average Grant Date Fair Value, Forfeited	15.77
Weighted-Average Grant Date Fair Value, Issued and unvested, Ending Balance	9.26	$ 6.76
Weighted-Average Grant Date Fair Value, Issued and expected to vest	$ 9.26

Transition Costs - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
General and Administrative Expenses [Member]
Transition Costs [Line Items]
Non-cash charges associated with modifications to existing stock grants held by the retiring executives and expenses associated with the onboarding of the Company's new President and CEO	$ 9,602

Business Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net revenues									$ 181,743	$ 167,064	$ 128,198
Operating income (loss)	$ 12,512	$ 10,857	$ 5,558	$ (498)	$ 10,161	$ 7,319	$ 6,887	$ 15,871	28,429	40,238	20,265
Depreciation and amortization									7,222	6,402	5,640
Capital expenditures									6,344	4,337	4,353
Total assets	315,571				296,201				315,571	296,201
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues									85,635	91,965	95,984
Operating income (loss)									(20,123)	(2,706)	15,606
Depreciation and amortization									3,755	3,170	2,751
Capital expenditures									4,893	2,752	2,145
Total assets	190,178				192,352				190,178	192,352
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues									96,108	75,099	32,214
Operating income (loss)									48,552	42,944	4,659
Depreciation and amortization									3,467	3,232	2,889
Capital expenditures									1,451	1,585	$ 2,208
Total assets	$ 125,393				$ 103,849				$ 125,393	$ 103,849

Business Segment Information - Presentation of Total Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 24,299	$ 21,372
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	18,776	16,160
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	5,192	5,083
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 331	$ 129

Commitments and Contingencies - Schedule for Future Minimum Lease Payments under Operating Lease Agreements (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2019	$ 903
2020	902
2021	877
2022	850
2023	506
Thereafter	737
Total	$ 4,775

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Contractual Obligation Fiscal Year Maturity [Line Items]
Rent expense	$ 1,461	$ 852	$ 715
Employment Agreements [Member]
Contractual Obligation Fiscal Year Maturity [Line Items]
Future minimum payments	1,779
Required salary payment as per agreements with employees, second year	1,779
Required salary payment as per agreements with employees, third year	$ 980

Commitments and Contingencies - Schedule of Outstanding Non-cancelable Purchase Commitments (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Purchase Obligation Fiscal Year Maturity [Abstract]
2019	$ 9,683
2020	402
2021	19
2022	19
2023	17
Total	$ 10,140

Retirement Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	$ 4,000
Contributed to plan, net of forfeitures	721,000	$ 617,000	$ 619,000
Value of the assets associated with the plan	3,884,000	3,514,000
Total obligation under plan		3,884,000	3,514,000
RRSP [Member] \| DNA Genotek [Member]
Defined Benefit Plan Disclosure [Line Items]
Employee contributions	2,000
Contributed to plan, net of forfeitures	$ 163,000	$ 145,000	$ 134,000

Quarterly Data - Summary of Quarterly Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 50,246	$ 45,885	$ 43,625	$ 41,987	$ 52,028	$ 42,314	$ 40,176	$ 32,546
Costs and expenses	37,734	35,028	38,067	42,485	41,867	34,995	33,289	16,675
Operating income	12,512	10,857	5,558	(498)	10,161	7,319	6,887	15,871	$ 28,429	$ 40,238	$ 20,265
Other income, net	1,629	510	736	412	118	113	96	467	3,287	794	58
Income before income taxes	14,141	11,367	6,294	(86)	10,279	7,432	6,983	16,338	31,716	41,032	20,323
Income tax expense	3,843	3,271	2,173	2,033	2,963	1,669	1,555	3,897	11,320	10,084	603
NET INCOME	$ 10,298	$ 8,096	$ 4,121	$ (2,119)	$ 7,316	$ 5,763	$ 5,428	$ 12,441	$ 20,396	$ 30,948	$ 19,720
Earnings (loss) per share
Basic	$ 0.17	$ 0.13	$ 0.07	$ (0.03)	$ 0.12	$ 0.10	$ 0.09	$ 0.22	$ 0.33	$ 0.52	$ 0.35
Diluted	$ 0.16	$ 0.13	$ 0.07	$ (0.03)	$ 0.12	$ 0.09	$ 0.09	$ 0.21	$ 0.33	$ 0.51	$ 0.35

Quarterly Data - Summary of Quarterly Results of Operations (Parenthetical) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Gain on litigation settlement		$ 12,500
Ancestry Com Dna Llc And Its Contract Manufacturer Litigation
Gain on litigation settlement	$ 12,500

Subsequent Events - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Jan. 04, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Acquisition related costs		$ 1,235,000
Corebiome Inc. and Novosanis NV [Member] \| Subsequent Event
Subsequent Event [Line Items]
Purchase price	$ 12,014